The clinical-stage pharma company Acer Therapeutics Inc. (Nasdaq:ACER) has begun screening patients for its Phase 3 DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical study of EDSIVO (celiprolol) to treat COL3A1-positive vascular Ehlers-Danlos syndrome (vEDS).
There are presently no FDA-approved drugs available for vEDS, which is associated with a risk of internal bleeding, internal injuries and aneurysms.
The study will determine whether the Beta 1 adrenergic receptor antagonist celiprolol reduces the likelihood of vEDS-related clinical events needing medical attention. Such events, including cardiac or arterial events, uterine rupture or intestinal rupture, can sometimes be fatal.
Vascular Ehlers-Danos syndrome is relatively rare, affecting between 6,000 and 8,000 people in the U.S., according to the VEDS Movement.
To optimize recruiting, Acer Therapeutics will use a decentralized study design. The company aims…